Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
4 days ago
4 days ago
touchMDT for touchONCOLOGY
MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC
Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC).
The multidisciplinary team:
Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA
This touchPODCAST is for HCPs outside of the UK only.
This activity is supported by an independent medical education funding request from AstraZeneca.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.